Pemigatinib demonstrates proven therapeutic activity in patients with previously treated locally advanced/metastatic cholangiocarcinoma and FGFR2 fusions/rearrangements, as well as in patients with recurrent/refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangements.
Chlorocarcinoma:
When selecting patients with locally advanced or metastatic cholangiocarcinoma for pemigatinib treatment, confirmation of FGFR2 fusions or other rearrangements in the tumor using an FDA-approved assay is required.
Myeloid/Lymphoid Neoplasms (MLNs):
When selecting patients with recurrent or refractory MLNs for pemigatinib treatment, confirmation of FGFR1 rearrangements in the tumor is required. However, there is currently no FDA-approved assay for detecting FGFR1 rearrangements in MLN patients to screen for pemigatinib treatment.
